Blood-Based Molecular Test Improves Early Detection of Colorectal Cancer
By LabMedica International staff writers Posted on 03 Mar 2015 |
Image: The Colox test kit for the detection of colorectal cancer (Photo courtesy of Diagnoplex SA).
A convenient blood test can be ordered by a physician during a routine medical checkup to accurately and reliably detect both adenomatous polyps and early stages of colorectal cancer.
Mononuclear cells (PBMCs) are particularly responsive to growing adenomatous polyps and colorectal carcinomas and determining the expression of 29 genes in PBMCs provides a telltale sign of the early stages of colorectal cancer.
The new molecular blood test for the detection of colorectal cancer and precancerous lesions such as adenomatous polyps is called Colox; it has been approved for sale in Europe, and has been launched commercially in Switzerland. Colox is available as a Laboratory Developed Test and is highly suited to standard medical laboratory workflow and is also available as a Conformité Européenne (CE) registered kit.
The Colox test was originally developed by Diagnoplex SA (Epalinges, Switzerland) and represents a new generation of cancer diagnostic tests based on the response of the organism against the tumor. The molecular diagnostics company Novigenix SA (Epalinges, Switzerland) announced it has acquired Colox. Gene expression data are interpreted by Novigenix's proprietary algorithm which generates the Colox test report. This algorithm is based on classifier combinations derived from mathematical analytical methods that underpin the reliability of the test.
Colox has been tested in a multicenter clinical study at the Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland). Gian Dorta, MD, a professor who led the study said, “Colox accurately and reliably detects both adenomatous polyps and early stages of colorectal cancer with a convenient blood test that can be ordered as part of a routine medical checkup. As a result Colox has the potential to dramatically increase screening compliance and reduce the mortality rate from this deadly disease.”
Brian B Hashemi, PhD MBA, Executive Chairman of Novigenix, said, “Our vision is to support physicians and the healthcare community in significantly reducing cancer mortality through the early diagnosis and intervention of colorectal cancer. We are committed to making Colox available to physicians and patients across Switzerland, followed by expansion in other European countries. Colorectal cancer is today the third most lethal cancer, but can be largely prevented if detected early by an accurate, reliable, and convenient test such as Colox.”
Related Links:
Diagnoplex SA
Novigenix SA
Centre Hospitalier Universitaire
Mononuclear cells (PBMCs) are particularly responsive to growing adenomatous polyps and colorectal carcinomas and determining the expression of 29 genes in PBMCs provides a telltale sign of the early stages of colorectal cancer.
The new molecular blood test for the detection of colorectal cancer and precancerous lesions such as adenomatous polyps is called Colox; it has been approved for sale in Europe, and has been launched commercially in Switzerland. Colox is available as a Laboratory Developed Test and is highly suited to standard medical laboratory workflow and is also available as a Conformité Européenne (CE) registered kit.
The Colox test was originally developed by Diagnoplex SA (Epalinges, Switzerland) and represents a new generation of cancer diagnostic tests based on the response of the organism against the tumor. The molecular diagnostics company Novigenix SA (Epalinges, Switzerland) announced it has acquired Colox. Gene expression data are interpreted by Novigenix's proprietary algorithm which generates the Colox test report. This algorithm is based on classifier combinations derived from mathematical analytical methods that underpin the reliability of the test.
Colox has been tested in a multicenter clinical study at the Centre Hospitalier Universitaire Vaudois (Lausanne, Switzerland). Gian Dorta, MD, a professor who led the study said, “Colox accurately and reliably detects both adenomatous polyps and early stages of colorectal cancer with a convenient blood test that can be ordered as part of a routine medical checkup. As a result Colox has the potential to dramatically increase screening compliance and reduce the mortality rate from this deadly disease.”
Brian B Hashemi, PhD MBA, Executive Chairman of Novigenix, said, “Our vision is to support physicians and the healthcare community in significantly reducing cancer mortality through the early diagnosis and intervention of colorectal cancer. We are committed to making Colox available to physicians and patients across Switzerland, followed by expansion in other European countries. Colorectal cancer is today the third most lethal cancer, but can be largely prevented if detected early by an accurate, reliable, and convenient test such as Colox.”
Related Links:
Diagnoplex SA
Novigenix SA
Centre Hospitalier Universitaire
Latest Industry News
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million